Pathophysiology of Fever
Fever represents a regulated upward shift in the hypothalamic thermoregulatory set-point mediated by prostaglandin E2 (PGE2), triggered either by peripheral immune activation through cytokine release or by direct Toll-like receptor (TLR) engagement in the hypothalamic vasculature. 1, 2
Core Mechanism: The Hypothalamic Set-Point
Fever fundamentally differs from hyperthermia in that it involves intact thermoregulatory mechanisms with an elevated set-point, whereas hyperthermia represents uncontrolled temperature elevation where thermoregulatory mechanisms are overwhelmed. 1 This distinction is critical because antipyretics effectively reduce fever by lowering the hypothalamic set-point but are completely ineffective for hyperthermia, which requires external cooling. 1, 3
Peripheral Initiation Pathways
Exogenous Pyrogens and Immune Activation
The fever cascade begins when exogenous pyrogens (bacterial lipopolysaccharides, other microbial products) or endogenous inflammatory stimuli activate peripheral immune cells. 4, 5 These activated immune cells—including blood leukocytes and hepatic immune cells—release proinflammatory cytokines, particularly interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). 6, 2
Dual Transmission Routes to the Brain
Pyrogenic signals reach the central nervous system through two distinct pathways: 4, 5
Humoral Pathway: Peripheral cytokines and prostaglandins produced by immune cells travel directly through the bloodstream to the preoptic area of the hypothalamus via circumventricular organs—specialized brain regions lacking a blood-brain barrier. 4
Neuronal Pathway: The same cytokines indirectly stimulate vagal sensory neurons, transmitting pyrogenic signals through afferent neural pathways to the hypothalamic thermoregulatory center. 4, 6
Central Mechanisms in the Hypothalamus
Direct TLR Engagement
Modern understanding reveals that microbial products can cause fever independently of cytokine production by directly engaging Toll-like receptors (TLRs) on the vascular endothelium supplying the anterior hypothalamus. 2 This explains why specific blockade of IL-1 or TNF activity fails to prevent fever during actual infections—the TLR pathway provides an alternative route. 2
The PGE2 Final Common Pathway
Regardless of whether fever is initiated by cytokine receptors or TLR triggering, both pathways converge on cyclooxygenase-2 (COX-2) activation and prostaglandin E2 (PGE2) production. 2 PGE2 acts on temperature-sensitive neurons in the preoptic hypothalamic region, raising the thermoregulatory set-point and activating heat-generating and heat-conserving mechanisms. 6, 2, 7
Thermoregulatory Effector Activation
Once the hypothalamic set-point is elevated, the body perceives its current temperature as "too cold" and activates: 7
- Cold thermogenesis (shivering, increased metabolic heat production)
- Vasomotion (peripheral vasoconstriction to conserve heat)
- Behavioral responses (seeking warmth, reducing activity)
These mechanisms persist until core temperature matches the new elevated set-point. 7
Fever Resolution Phase
During defervescence, temperature thresholds for cold thermogenesis move downward while thresholds for heat-dissipating mechanisms (vasodilation, sweating) remain elevated, creating an expanded interthreshold zone. 7 This allows body cooling and fever termination. 7
Clinical Context: Non-Infectious Hyperthermia
Drug-Induced Fever
Drug hypersensitivity produces fever through a distinct mechanism with a characteristic temporal pattern: mean lag time of 21 days (median 8 days) between drug initiation and fever onset. 8, 9, 3 Fever resolves within 1-3 days (occasionally up to 7 days) after discontinuing the offending agent. 8, 9, 3 This represents a diagnosis of exclusion after ruling out infection. 9
Malignant Hyperthermia and Neuroleptic Malignant Syndrome
These life-threatening syndromes involve fundamentally different mechanisms than true fever: 8
Malignant hyperthermia results from genetically determined dysregulation of skeletal muscle calcium control, causing intense muscle contraction and heat generation, typically triggered by succinylcholine or halogenated anesthetics. 8
Neuroleptic malignant syndrome presents with core temperature often >102.5°F, generalized "lead-pipe" muscle rigidity, altered mental status, autonomic instability, and elevated creatine phosphokinase. 3 It does not respond to antipyretics and requires immediate drug discontinuation and aggressive external cooling. 3
Important Clinical Caveats
Not all infected patients develop fever—elderly patients, those with open wounds or burns, patients receiving extracorporeal therapies or continuous renal replacement, and those on anti-inflammatory medications may remain euthermic or hypothermic despite life-threatening infection. 8 The absence of fever in infected patients is associated with worse outcomes. 8
Human population baseline temperature has been decreasing by 0.03°C per birth decade over the past 157 years, affecting fever definitions. 8